Dr Tobias Reichmuth talks taking hardcore science to market without biotech approval risk and the catalyst that is translational research.
We were lucky enough to attend the Longevity Investors Conference last month; this key event attracts those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. To put it succinctly, as MIT Tech Review did recently, LIC "brings academic scientists and biotech companies together with deep-pocketed investors. We’re talking millionaires and billionaires."
One of the driving forces behind the Longevity Investors Conference is Dr Tobias Reichmuth; a company-builder since the age of 21, Reichmuth has invested in more than 20 startups and is one of the founding partners of Maximon, the longevity company building. Along with his Maximon colleague Marc P Bernegger, Riechmuth launched the Longevity Investors Conference, and we couldn't pass up the chance to grab some time with him to discuss the current longevity market.
------------------------------
Visit Longevity.Technology - bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter - bit.ly/3AMIXuq
Facebook - bit.ly/3z8H1v5
Instagram - bit.ly/3IDvVRX
Linkedin - bit.ly/3yIfDmf